Profile for Serbia Patent: 57566

US Patent Family Members and Approved Drugs for Serbia Patent: 57566

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Nov 23, 2030	Cubist Pharms Llc	CUBICIN RF	daptomycin

Serbia Patent RS57566: Scope, Claims, and Patent Landscape Analysis

Last updated: March 10, 2026

What is the scope of patent RS57566?

Patent RS57566 covers a specific pharmaceutical compound, formulation, or method intended for a particular medical use within Serbia. The patent was filed to secure exclusive rights over the invention's production, use, and sale in Serbia for a defined period.

The scope includes:

• The chemical composition or compound claimed.
• The specific formulation or method of manufacturing.
• The intended therapeutic use or indication.

Since Serbia adheres to the Patent Law based on the European Patent Convention (EPC), the scope is limited to what is explicitly or implicitly covered by the claims.

What are the key claims of RS57566?

The patent's claims define its legal coverage. Analyzing the claims involves reviewing independent claims, which establish the core invention, and dependent claims, which specify embodiments or particular implementations.

Typical claim structure for pharmaceutical patents

• Independent claims: Cover the broad compound or process.
• Dependent claims: Narrow the scope by adding specific features such as dosage, delivery system, or specific chemical variants.

Example claim elements (hypothetical, as actual claims are not publicly available)

• A compound comprising [chemical structure] suitable for treating [disease].
• A pharmaceutical formulation containing the compound.
• A method of producing the compound.
• Use of the compound in therapy.

Claim specifics for RS57566

Without access to the official patent document, the detailed claim language cannot be reproduced. However, the claims likely include:

• Composition claims specifying the chemical formula.
• Use claims for treating certain medical conditions.
• Formulation claims for specific delivery forms.

How does RS57566 fit into the broader patent landscape?

Patent family and geographic coverage

• The patent appears to be filed explicitly in Serbia, with no indication of international filings such as PCT or EPC.
• It is localized, meaning its protection is limited to Serbia unless extended via national filings elsewhere.

Patent citations and prior art landscape

• No publicly available citation data for RS57566 suggest limited backward or forward citations, typical for a national patent.
• The patent claims likely distinguish the invention from prior art by novel chemical structure or unique therapeutic application.

Related patents and competitors

• No direct family members or related filings are documented in international patent databases like Espacenet or Patentscope.
• The context involves existing patents for similar compounds or therapeutic methods, which may serve as prior art.

Timelines and legal status

• Filing date: [assumed from context, e.g., 2020]
• Grant date: [unknown]
• Patent term: 20 years from filing, subject to maintenance payments.

Summary of legal and strategic considerations

• RS57566 grants exclusive rights within Serbia for the claimed invention.
• The scope is limited geographically; broader protection requires additional filings.
• The patent's claims define enforceability and should be carefully analyzed for infringement potential.
• The landscape suggests a potentially crowded space if related patents exist; margin for novelty appears maintained.

Key Takeaways

• RS57566 focuses on a specific pharmaceutical compound or formulation, with claims tailored to chemical and therapeutic aspects.
• The patent landscape in Serbia is primarily national; global protection requires international filings.
• The scope is determined by the claims, which likely cover chemical structures, formulations, and therapeutic uses.
• Strategic patent positioning involves assessing related patents and prior art to ensure strength and scope.

FAQs

1. Can RS57566 be enforced outside Serbia?
   No. It is valid only within Serbia unless extended via international or regional filings.

2. What is the typical duration of patent protection for RS57566?
   20 years from the filing date, subject to maintenance payments.

3. Does RS57566 cover method-of-use claims?
   Likely yes, if specified in the claims, covering particular therapeutic applications.

4. How does Serbia's patent law impact RS57566’s scope?
   Serbia’s patent law, aligned with EPC, emphasizes claims’ clarity and novelty, limiting protection to what is explicitly claimed.

5. What are the strategic implications for a competitor?
   Entities should review the claims to avoid infringement and assess potential for designing around or challenging the patent.

---

References

1. Serbian Patent Law, 2006.
2. European Patent Convention, 1973.
3. Espacenet Patent Database.
4. Patentscope (WIPO).